MYRIAD GENETICS INC
About MYRIAD GENETICS INC
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $824.5M
- Net income
- -$365.9M
- Total assets
- $706.6M
- Market cap
- $431.6M
- Gross margin
- 69.9%
- Operating margin
- -47.0%
- Net margin
- -44.4%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $824.5M
- Cost of revenue
- $247.9M
- Gross profit
- $576.6M
- Operating expenses
- $963.8M
- Operating income
- -$387.2M
- Income tax
- -$29.2M
- Net income
- -$365.9M
- EPS (basic)
- $-3.95
- EPS (diluted)
- $-3.95
Balance sheet
- Total assets
- $706.6M
- Current assets
- $332.6M
- Total liabilities
- $338.6M
- Current liabilities
- $133.8M
- Shareholders’ equity
- $368.0M
Cash flow
- Operating cash flow
- $1.8M
- Investing cash flow
- -$27.4M
- Financing cash flow
- $64.2M
- Net cash flow
- $39.4M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $431.6M
- EPS (diluted)
- $-3.95
- Shares outstanding
- 97.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 6, 1995
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $365.9M in FY2025.
- Revenue grew 19% from FY2021 to FY2025.
- Gross margin of 69.9%, net margin -44.4%.
- Trading 46% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review MYRIAD GENETICS INC.
Write a review
News about MYRIAD GENETICS INC
News & sentiment via Polygon.io
